In recent years, tyrosine kinase inhibitors (TKI) towards the vascular endothelial growth factor (VEGF), the mammalian target of rapamycin (mTOR) inhibitor, clustered, regularly interspaced short palindromic repeats-Cas9 (CRISPR-Cas9), small molecule inhibitors, and immune checkpoint inhibitors have had promising clinical outcomes against advanced RCC [6,7,8,9]. Here, MTOR is linked to renal cell carcinoma.